<code id='9D3C62AAFC'></code><style id='9D3C62AAFC'></style>
    • <acronym id='9D3C62AAFC'></acronym>
      <center id='9D3C62AAFC'><center id='9D3C62AAFC'><tfoot id='9D3C62AAFC'></tfoot></center><abbr id='9D3C62AAFC'><dir id='9D3C62AAFC'><tfoot id='9D3C62AAFC'></tfoot><noframes id='9D3C62AAFC'>

    • <optgroup id='9D3C62AAFC'><strike id='9D3C62AAFC'><sup id='9D3C62AAFC'></sup></strike><code id='9D3C62AAFC'></code></optgroup>
        1. <b id='9D3C62AAFC'><label id='9D3C62AAFC'><select id='9D3C62AAFC'><dt id='9D3C62AAFC'><span id='9D3C62AAFC'></span></dt></select></label></b><u id='9D3C62AAFC'></u>
          <i id='9D3C62AAFC'><strike id='9D3C62AAFC'><tt id='9D3C62AAFC'><pre id='9D3C62AAFC'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:Wikipedia    Page View:73656
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In